APTO - Aptose Biosciences Inc Stock Price, Fair Value and News

$0.19-0.05 (-20.83%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

APTO Price Action

Last 7 days

-47.2%

Last 30 days

-52.5%

Last 90 days

-52.5%

Trailing 12 Months

-92.2%

APTO RSI Chart

APTO Valuation

Market Cap

3.7M

Price/Earnings (Trailing)

-0.1

Price/Free Cashflow

-0.1

APTO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

APTO Fundamentals

APTO Earnings

Earnings (TTM)

-35.8M

Earnings Growth (Yr)

39.26%

Earnings Growth (Qtr)

4.12%

APTO Profitability

Return on Equity

391.94%

Return on Assets

-327.57%

Free Cashflow Yield

-1.0K%

APTO Investor Care

Shares Dilution (1Y)

149.73%

Diluted EPS (TTM)

-3.1

Revenue & Growth

About Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

CEO	Dr. William G. Rice Ph.D.
WEBSITE	aptose.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	35

Aptose Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Aptose Biosciences Inc? What does APTO stand for in stocks?

APTO is the stock ticker symbol of Aptose Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aptose Biosciences Inc (APTO)?

As of Fri Nov 22 2024, market cap of Aptose Biosciences Inc is 3.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APTO stock?

You can check APTO's fair value in chart for subscribers.

Is Aptose Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether APTO is over valued or under valued. Whether Aptose Biosciences Inc is cheap or expensive depends on the assumptions which impact Aptose Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APTO.

What is 5 year return on Aptose Biosciences Inc's stock?

In the past 10 years, Aptose Biosciences Inc has provided -0.47 (multiply by 100 for percentage) rate of return.